

## Special Issue on **Chemopreventive Compounds/Agents: Drugs for the Treatment and Prevention of Carcinomas**

# CALL FOR PAPERS

The increasing understanding of cancer cell pathobiology has shown the way to develop molecular approaches to treating neoplasm and to the decrease of mortality rates. These advances have also been influencing an active development of chemopreventive strategies that might reduce cancer incidence or counter progression of disease.

Chemoprevention includes the use of natural, synthetic, or biological agents to reverse, suppress, or prevent either the initial phases of carcinogenesis or the progression of premalignant cells to invasive disease.

Carcinoma is the most common type of cancer. It is initiated in the epithelial tissue of the skin or in the tissue that lines others organs, such as the liver, breast, and prostate. These comprise carcinoma in situ, invasive carcinoma, and metastatic carcinoma.

The aim of this special issue is to highlight the relevance of chemoprotective compounds with anticancer potential inhibiting tumor initiation, promotion, and progression.

The understanding of the molecular mechanism of these compounds will shed lights on the prevention of carcinoma and new therapeutic strategies and will pave of the generation of synthetic compounds with clinical potential.

The studies of these mechanisms are of great importance for the search of new compounds with antitumor properties to the treatment of hepatocellular carcinoma, skin cancer, breast cancer, and prostate cancer, among others.

Potential topics include but are not limited to the following:

- ▶ Inorganic compounds
- ▶ Organic compounds
- ▶ Nanotechnology
- ▶ Plant extracts
- ▶ Dietary compounds
- ▶ Drugs pharmacology

Authors can submit their manuscripts through the Manuscript Tracking System at <https://mts.hindawi.com/submit/journals/acp/ccc/>.

Papers are published upon acceptance, regardless of the Special Issue publication date.

### **Lead Guest Editor**

Cesar Echeverria, Bernardo O'Higgins University, Santiago, Chile  
[cesar.echeverria@ubo.cl](mailto:cesar.echeverria@ubo.cl)

### **Guest Editors**

Juan F. Santibanez, University of Belgrade, Belgrade, Serbia  
[jfsantibanez@imi.bg.ac.rs](mailto:jfsantibanez@imi.bg.ac.rs)

Jesús Espada, Ramón y Cajal University Hospital, Madrid, Spain  
[jespada@iib.uam.es](mailto:jespada@iib.uam.es)

Victor H. Villar, Beatson Institute, Glasgow, UK  
[v.villar@beatson.gla.ac.uk](mailto:v.villar@beatson.gla.ac.uk)

### **Submission Deadline**

Friday, 15 June 2018

### **Publication Date**

November 2018